|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
5
|
Ciprofloxacin
|
Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft
|
1797513
|
440276
|
Ciprofloxacin & Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft
|
## Chronograph ##

## Basic demographic table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
26
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
185
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
18
|
69
|
Sex
|
gender = FEMALE
|
619
|
62
|
Sex
|
gender = FEMALE
|
104
|
56
|
Sex
|
gender = FEMALE
|
546
|
55
|
|
|
gender = MALE
|
8
|
31
|
|
gender = MALE
|
381
|
38
|
|
gender = MALE
|
81
|
44
|
|
gender = MALE
|
454
|
45
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
0
|
0
|
|
(20,30]
|
3
|
0
|
|
(20,30]
|
1
|
1
|
|
(20,30]
|
8
|
1
|
|
|
(30,40]
|
0
|
0
|
|
(30,40]
|
24
|
2
|
|
(30,40]
|
5
|
3
|
|
(30,40]
|
13
|
1
|
|
|
(40,50]
|
1
|
4
|
|
(40,50]
|
55
|
6
|
|
(40,50]
|
7
|
4
|
|
(40,50]
|
44
|
4
|
|
|
(50,60]
|
1
|
4
|
|
(50,60]
|
73
|
7
|
|
(50,60]
|
13
|
7
|
|
(50,60]
|
55
|
6
|
|
|
(60,70]
|
6
|
23
|
|
(60,70]
|
209
|
21
|
|
(60,70]
|
35
|
19
|
|
(60,70]
|
224
|
22
|
|
|
(70,80]
|
13
|
50
|
|
(70,80]
|
334
|
33
|
|
(70,80]
|
62
|
34
|
|
(70,80]
|
386
|
39
|
|
|
(80,90]
|
3
|
12
|
|
(80,90]
|
229
|
23
|
|
(80,90]
|
50
|
27
|
|
(80,90]
|
225
|
22
|
|
|
(90,110]
|
2
|
8
|
|
(90,110]
|
73
|
7
|
|
(90,110]
|
12
|
6
|
|
(90,110]
|
45
|
4
|
|
|
Median
|
73
|
IQR=(67, 80)
|
|
Median
|
74
|
IQR=(67, 83)
|
|
Median
|
75
|
IQR=(68, 83)
|
|
Median
|
74
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 26)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 26)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
7.7
|
1.4
|
-0.31
|
|
25 - 29
|
0
|
0.3
|
0.08
|
Visual system disorder
|
38.5
|
33.9
|
-0.10
|
|
30 - 34
|
0
|
0.7
|
0.12
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
0
|
1.0
|
0.14
|
Atrial fibrillation
|
46.2
|
29.0
|
-0.36
|
|
40 - 44
|
3.8
|
2.1
|
-0.10
|
Cerebrovascular disease
|
11.5
|
8.6
|
-0.10
|
|
45 - 49
|
0
|
3.3
|
0.26
|
Coronary arteriosclerosis
|
61.5
|
29.1
|
-0.69
|
|
50 - 54
|
0
|
2.4
|
0.22
|
Heart disease
|
96.2
|
58.0
|
-1.02
|
|
55 - 59
|
3.8
|
5.1
|
0.06
|
Heart failure
|
53.8
|
25.6
|
-0.60
|
|
60 - 64
|
0
|
4.3
|
0.30
|
Ischemic heart disease
|
26.9
|
16.2
|
-0.26
|
|
65 - 69
|
23.1
|
14.9
|
-0.21
|
Peripheral vascular disease
|
57.7
|
30.0
|
-0.58
|
|
70 - 74
|
26.9
|
17.2
|
-0.24
|
Pulmonary embolism
|
3.8
|
3.2
|
-0.04
|
|
75 - 79
|
11.5
|
15.0
|
0.10
|
Venous thrombosis
|
15.4
|
8.6
|
-0.21
|
|
80 - 84
|
19.2
|
13.5
|
-0.16
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
3.8
|
11.1
|
0.28
|
Hematologic neoplasm
|
23.1
|
8.2
|
-0.42
|
|
90 - 94
|
7.7
|
5.4
|
-0.09
|
Malignant lymphoma
|
11.5
|
3.5
|
-0.31
|
|
95 - 99
|
0
|
2.9
|
0.24
|
Malignant neoplasm of anorectum
|
0
|
1.3
|
0.16
|
|
100 - 104
|
0
|
0.8
|
0.13
|
Malignant neoplastic disease
|
50.0
|
26.2
|
-0.51
|
|
Gender: female
|
69.2
|
61.9
|
-0.15
|
Malignant tumor of breast
|
3.8
|
3.8
|
0.00
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
7.7
|
4.0
|
-0.16
|
|
Acute respiratory disease
|
50.0
|
23.8
|
-0.56
|
Malignant tumor of lung
|
15.4
|
2.5
|
-0.46
|
|
Attention deficit hyperactivity disorder
|
0
|
0.1
|
0.04
|
Malignant tumor of urinary bladder
|
3.8
|
2.5
|
-0.08
|
|
Chronic liver disease
|
15.4
|
3.3
|
-0.42
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
30.8
|
11.3
|
-0.49
|
Agents acting on the renin-angiotensin system
|
73.1
|
68.0
|
-0.11
|
|
Crohn’s disease
|
3.8
|
1.2
|
-0.17
|
Antibacterials for systemic use
|
65.4
|
48.4
|
-0.35
|
|
Dementia
|
7.7
|
13.1
|
0.18
|
Antidepressants
|
73.1
|
57.5
|
-0.33
|
|
Depressive disorder
|
7.7
|
10.9
|
0.11
|
Antiepileptics
|
30.8
|
34.1
|
0.07
|
|
Diabetes mellitus
|
84.6
|
50.6
|
-0.78
|
Antiinflammatory and antirheumatic products
|
42.3
|
36.4
|
-0.12
|
|
Gastroesophageal reflux disease
|
7.7
|
13.9
|
0.20
|
Antineoplastic agents
|
11.5
|
12.1
|
0.02
|
|
Gastrointestinal hemorrhage
|
19.2
|
6.3
|
-0.39
|
Antipsoriatics
|
0
|
0.4
|
0.09
|
|
Human immunodeficiency virus infection
|
0
|
0.7
|
0.12
|
Antithrombotic agents
|
57.7
|
51.2
|
-0.13
|
|
Hyperlipidemia
|
38.5
|
25.4
|
-0.28
|
Beta blocking agents
|
73.1
|
63.4
|
-0.21
|
|
Hypertensive disorder
|
11.5
|
5.0
|
-0.24
|
Calcium channel blockers
|
73.1
|
53.2
|
-0.42
|
|
Lesion of liver
|
19.2
|
3.7
|
-0.50
|
Diuretics
|
57.7
|
66.0
|
0.17
|
|
Obesity
|
3.8
|
7.0
|
0.14
|
Drugs for acid related disorders
|
42.3
|
48.4
|
0.12
|
|
Osteoarthritis
|
53.8
|
37.1
|
-0.34
|
Drugs for obstructive airway diseases
|
34.6
|
37.8
|
0.07
|
|
Pneumonia
|
11.5
|
7.1
|
-0.15
|
Drugs used in diabetes
|
46.2
|
53.7
|
0.15
|
|
Psoriasis
|
0
|
1.8
|
0.19
|
Immunosuppressants
|
7.7
|
5.0
|
-0.11
|
|
Renal impairment
|
73.1
|
26.2
|
-1.06
|
Lipid modifying agents
|
84.6
|
71.3
|
-0.33
|
|
Rheumatoid arthritis
|
7.7
|
6.2
|
-0.06
|
Opioids
|
42.3
|
31.4
|
-0.23
|
|
Schizophrenia
|
23.1
|
6.8
|
-0.47
|
Psycholeptics
|
57.7
|
52.8
|
-0.10
|
|
Ulcerative colitis
|
0
|
0.2
|
0.06
|
Psychostimulants, agents used for adhd and nootropics
|
11.5
|
14.3
|
0.08
|
|
Urinary tract infectious disease
|
53.8
|
21.4
|
-0.71
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 185)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 185)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Urinary tract infectious disease
|
34.6
|
19.1
|
-0.36
|
|
25 - 29
|
0.5
|
0.6
|
0.01
|
Viral hepatitis C
|
4.3
|
1.5
|
-0.17
|
|
30 - 34
|
1.6
|
1.0
|
-0.05
|
Visual system disorder
|
49.2
|
40.1
|
-0.18
|
|
35 - 39
|
1.1
|
0.2
|
-0.11
|
Medical history: Cardiovascular disease
|
|
|
|
|
40 - 44
|
2.2
|
0.9
|
-0.10
|
Atrial fibrillation
|
49.7
|
26.2
|
-0.50
|
|
45 - 49
|
1.6
|
3.0
|
0.09
|
Cerebrovascular disease
|
20.0
|
8.2
|
-0.34
|
|
50 - 54
|
2.2
|
2.8
|
0.04
|
Coronary arteriosclerosis
|
51.4
|
29.0
|
-0.47
|
|
55 - 59
|
4.3
|
2.9
|
-0.08
|
Heart disease
|
86.5
|
57.6
|
-0.68
|
|
60 - 64
|
1.6
|
2.9
|
0.09
|
Heart failure
|
52.4
|
22.6
|
-0.65
|
|
65 - 69
|
14.6
|
16.1
|
0.04
|
Ischemic heart disease
|
25.9
|
12.6
|
-0.34
|
|
70 - 74
|
17.8
|
22.7
|
0.12
|
Peripheral vascular disease
|
44.3
|
27.1
|
-0.37
|
|
75 - 79
|
15.7
|
17.1
|
0.04
|
Pulmonary embolism
|
6.5
|
2.6
|
-0.19
|
|
80 - 84
|
17.3
|
13.9
|
-0.09
|
Venous thrombosis
|
16.8
|
8.1
|
-0.26
|
|
85 - 89
|
10.3
|
10.0
|
-0.01
|
Medical history: Neoplasms
|
|
|
|
|
90 - 94
|
4.9
|
3.7
|
-0.06
|
Hematologic neoplasm
|
24.3
|
6.5
|
-0.51
|
|
95 - 99
|
2.7
|
1.9
|
-0.05
|
Malignant lymphoma
|
10.3
|
4.0
|
-0.25
|
|
100 - 104
|
1.6
|
0.3
|
-0.14
|
Malignant neoplasm of anorectum
|
3.2
|
1.7
|
-0.10
|
|
Gender: female
|
56.2
|
54.6
|
-0.03
|
Malignant neoplastic disease
|
54.1
|
26.6
|
-0.58
|
|
Medical history: General
|
|
|
|
Malignant tumor of breast
|
7.0
|
3.6
|
-0.15
|
|
Acute respiratory disease
|
35.7
|
21.5
|
-0.32
|
Malignant tumor of colon
|
8.1
|
4.1
|
-0.17
|
|
Attention deficit hyperactivity disorder
|
0
|
0.2
|
0.06
|
Malignant tumor of lung
|
4.9
|
4.1
|
-0.04
|
|
Chronic liver disease
|
7.0
|
2.6
|
-0.21
|
Malignant tumor of urinary bladder
|
6.5
|
2.6
|
-0.19
|
|
Chronic obstructive lung disease
|
21.1
|
8.9
|
-0.35
|
Medication use
|
|
|
|
|
Crohn’s disease
|
1.1
|
1.0
|
-0.01
|
Agents acting on the renin-angiotensin system
|
42.7
|
0
|
-1.22
|
|
Dementia
|
22.7
|
10.7
|
-0.33
|
Antibacterials for systemic use
|
38.4
|
0
|
-1.12
|
|
Depressive disorder
|
14.1
|
7.6
|
-0.21
|
Antidepressants
|
38.4
|
0
|
-1.12
|
|
Diabetes mellitus
|
73.0
|
50.5
|
-0.48
|
Antiepileptics
|
23.8
|
0
|
-0.79
|
|
Gastroesophageal reflux disease
|
26.5
|
13.7
|
-0.32
|
Antiinflammatory and antirheumatic products
|
23.8
|
0
|
-0.79
|
|
Gastrointestinal hemorrhage
|
8.1
|
4.9
|
-0.13
|
Antineoplastic agents
|
11.4
|
0
|
-0.51
|
|
Human immunodeficiency virus infection
|
1.6
|
0.5
|
-0.11
|
Antithrombotic agents
|
38.4
|
0
|
-1.12
|
|
Hyperlipidemia
|
34.1
|
24.3
|
-0.22
|
Beta blocking agents
|
34.6
|
0
|
-1.03
|
|
Hypertensive disorder
|
4.3
|
5.3
|
0.05
|
Calcium channel blockers
|
30.3
|
0
|
-0.93
|
|
Lesion of liver
|
5.9
|
3.4
|
-0.12
|
Diuretics
|
40.0
|
0
|
-1.15
|
|
Obesity
|
11.9
|
5.9
|
-0.21
|
Drugs for acid related disorders
|
30.8
|
0
|
-0.94
|
|
Osteoarthritis
|
61.1
|
38.1
|
-0.47
|
Drugs for obstructive airway diseases
|
22.7
|
0
|
-0.77
|
|
Pneumonia
|
12.4
|
5.4
|
-0.25
|
Drugs used in diabetes
|
35.1
|
0
|
-1.04
|
|
Psoriasis
|
2.2
|
1.7
|
-0.03
|
Immunosuppressants
|
3.8
|
0
|
-0.28
|
|
Renal impairment
|
41.6
|
22.5
|
-0.42
|
Lipid modifying agents
|
43.8
|
0
|
-1.25
|
|
Rheumatoid arthritis
|
8.6
|
6.0
|
-0.10
|
Opioids
|
33.5
|
0
|
-1.00
|
|
Schizophrenia
|
8.1
|
4.0
|
-0.17
|
Psycholeptics
|
42.7
|
0
|
-1.22
|
|
Ulcerative colitis
|
1.1
|
0.3
|
-0.09
|
Psychostimulants, agents used for adhd and nootropics
|
9.7
|
0
|
-0.46
|
## Drug vs. All ##
|
Characteristic
|
% (n = 185)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 185)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Urinary tract infectious disease
|
34.6
|
19.1
|
-0.36
|
|
25 - 29
|
0.5
|
0.6
|
0.01
|
Viral hepatitis C
|
4.3
|
1.5
|
-0.17
|
|
30 - 34
|
1.6
|
1.0
|
-0.05
|
Visual system disorder
|
49.2
|
40.1
|
-0.18
|
|
35 - 39
|
1.1
|
0.2
|
-0.11
|
Medical history: Cardiovascular disease
|
|
|
|
|
40 - 44
|
2.2
|
0.9
|
-0.10
|
Atrial fibrillation
|
49.7
|
26.2
|
-0.50
|
|
45 - 49
|
1.6
|
3.0
|
0.09
|
Cerebrovascular disease
|
20.0
|
8.2
|
-0.34
|
|
50 - 54
|
2.2
|
2.8
|
0.04
|
Coronary arteriosclerosis
|
51.4
|
29.0
|
-0.47
|
|
55 - 59
|
4.3
|
2.9
|
-0.08
|
Heart disease
|
86.5
|
57.6
|
-0.68
|
|
60 - 64
|
1.6
|
2.9
|
0.09
|
Heart failure
|
52.4
|
22.6
|
-0.65
|
|
65 - 69
|
14.6
|
16.1
|
0.04
|
Ischemic heart disease
|
25.9
|
12.6
|
-0.34
|
|
70 - 74
|
17.8
|
22.7
|
0.12
|
Peripheral vascular disease
|
44.3
|
27.1
|
-0.37
|
|
75 - 79
|
15.7
|
17.1
|
0.04
|
Pulmonary embolism
|
6.5
|
2.6
|
-0.19
|
|
80 - 84
|
17.3
|
13.9
|
-0.09
|
Venous thrombosis
|
16.8
|
8.1
|
-0.26
|
|
85 - 89
|
10.3
|
10.0
|
-0.01
|
Medical history: Neoplasms
|
|
|
|
|
90 - 94
|
4.9
|
3.7
|
-0.06
|
Hematologic neoplasm
|
24.3
|
6.5
|
-0.51
|
|
95 - 99
|
2.7
|
1.9
|
-0.05
|
Malignant lymphoma
|
10.3
|
4.0
|
-0.25
|
|
100 - 104
|
1.6
|
0.3
|
-0.14
|
Malignant neoplasm of anorectum
|
3.2
|
1.7
|
-0.10
|
|
Gender: female
|
56.2
|
54.6
|
-0.03
|
Malignant neoplastic disease
|
54.1
|
26.6
|
-0.58
|
|
Medical history: General
|
|
|
|
Malignant tumor of breast
|
7.0
|
3.6
|
-0.15
|
|
Acute respiratory disease
|
35.7
|
21.5
|
-0.32
|
Malignant tumor of colon
|
8.1
|
4.1
|
-0.17
|
|
Attention deficit hyperactivity disorder
|
0
|
0.2
|
0.06
|
Malignant tumor of lung
|
4.9
|
4.1
|
-0.04
|
|
Chronic liver disease
|
7.0
|
2.6
|
-0.21
|
Malignant tumor of urinary bladder
|
6.5
|
2.6
|
-0.19
|
|
Chronic obstructive lung disease
|
21.1
|
8.9
|
-0.35
|
Medication use
|
|
|
|
|
Crohn’s disease
|
1.1
|
1.0
|
-0.01
|
Agents acting on the renin-angiotensin system
|
42.7
|
0
|
-1.22
|
|
Dementia
|
22.7
|
10.7
|
-0.33
|
Antibacterials for systemic use
|
38.4
|
0
|
-1.12
|
|
Depressive disorder
|
14.1
|
7.6
|
-0.21
|
Antidepressants
|
38.4
|
0
|
-1.12
|
|
Diabetes mellitus
|
73.0
|
50.5
|
-0.48
|
Antiepileptics
|
23.8
|
0
|
-0.79
|
|
Gastroesophageal reflux disease
|
26.5
|
13.7
|
-0.32
|
Antiinflammatory and antirheumatic products
|
23.8
|
0
|
-0.79
|
|
Gastrointestinal hemorrhage
|
8.1
|
4.9
|
-0.13
|
Antineoplastic agents
|
11.4
|
0
|
-0.51
|
|
Human immunodeficiency virus infection
|
1.6
|
0.5
|
-0.11
|
Antithrombotic agents
|
38.4
|
0
|
-1.12
|
|
Hyperlipidemia
|
34.1
|
24.3
|
-0.22
|
Beta blocking agents
|
34.6
|
0
|
-1.03
|
|
Hypertensive disorder
|
4.3
|
5.3
|
0.05
|
Calcium channel blockers
|
30.3
|
0
|
-0.93
|
|
Lesion of liver
|
5.9
|
3.4
|
-0.12
|
Diuretics
|
40.0
|
0
|
-1.15
|
|
Obesity
|
11.9
|
5.9
|
-0.21
|
Drugs for acid related disorders
|
30.8
|
0
|
-0.94
|
|
Osteoarthritis
|
61.1
|
38.1
|
-0.47
|
Drugs for obstructive airway diseases
|
22.7
|
0
|
-0.77
|
|
Pneumonia
|
12.4
|
5.4
|
-0.25
|
Drugs used in diabetes
|
35.1
|
0
|
-1.04
|
|
Psoriasis
|
2.2
|
1.7
|
-0.03
|
Immunosuppressants
|
3.8
|
0
|
-0.28
|
|
Renal impairment
|
41.6
|
22.5
|
-0.42
|
Lipid modifying agents
|
43.8
|
0
|
-1.25
|
|
Rheumatoid arthritis
|
8.6
|
6.0
|
-0.10
|
Opioids
|
33.5
|
0
|
-1.00
|
|
Schizophrenia
|
8.1
|
4.0
|
-0.17
|
Psycholeptics
|
42.7
|
0
|
-1.22
|
|
Ulcerative colitis
|
1.1
|
0.3
|
-0.09
|
Psychostimulants, agents used for adhd and nootropics
|
9.7
|
0
|
-0.46
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
beta blocking agents
|
38
|
|
antithrombotic agents
|
30
|
|
all other therapeutic products
|
26
|
|
cardiovascular system
|
26
|
|
alimentary tract and metabolism
|
25
|
|
nervous system
|
25
|
|
antihistamines for systemic use
|
24
|
|
respiratory system
|
24
|
|
lipid modifying agents
|
22
|
|
lipid modifying agents, plain
|
22
|
|
stomatological preparations
|
22
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
21
|
|
hmg coa reductase inhibitors
|
20
|
|
agents acting on the renin-angiotensin system
|
19
|
|
antidepressants
|
19
|
|
antiinfectives for systemic use
|
19
|
|
calcium channel blockers
|
19
|
|
psychoanaleptics
|
19
|
|
analgesics
|
18
|
|
blood and blood forming organs
|
18
|
|
antibacterials for systemic use
|
17
|
|
dermatologicals
|
17
|
|
musculo-skeletal system
|
17
|
|
non-selective monoamine reuptake inhibitors
|
17
|
|
antiepileptics
|
16
|
|
cond_180_days
|
n_180_days
|
|
heart disease
|
25
|
|
pain
|
25
|
|
pain finding at anatomical site
|
25
|
|
vascular disorder
|
25
|
|
kidney disease
|
23
|
|
arthropathy
|
22
|
|
diabetes mellitus
|
22
|
|
inflammation of specific body organs
|
22
|
|
inflammation of specific body systems
|
22
|
|
measurement finding outside reference range
|
22
|
|
soft tissue lesion
|
22
|
|
pain of truncal structure
|
21
|
|
abnormal blood cell count
|
20
|
|
type 2 diabetes mellitus
|
20
|
|
anemia
|
19
|
|
cytopenia
|
19
|
|
erythropenia
|
19
|
|
hemoglobin level outside reference range
|
19
|
|
hemoglobin low
|
19
|
|
measurement finding below reference range
|
19
|
|
rbc count abnormal
|
19
|
|
rbc count low
|
19
|
|
renal impairment
|
19
|
|
structural disorder of heart
|
19
|
|
arteriosclerotic vascular disease
|
17
|